Piperaquine-Induced QTc Prolongation Decreases With Repeated Monthly Dihydroartemisinin-Piperaquine Dosing in Pregnant Ugandan Women [PDF]
Clinical Infectious Diseases, 2021 Abstract Background Intermittent preventive treatment with monthly dihydroartemisinin-piperaquine (DHA-PQ) is highly effective at preventing both malaria during pregnancy and placental malaria. Piperaquine prolongs the corrected QT interval (QTc), and it is possible that repeated monthly dosing could ...
Emma Hughes +11 more
openaire +5 more sources
Dihydroartemisinin-piperaquine versus chloroquine to treat vivax malaria in Afghanistan: an open randomized, non-inferiority, trial [PDF]
Malaria Journal, 2010 Background Afghanistan's national guidelines recommend chloroquine for the treatment of Plasmodium vivax infection, the parasite responsible for the majority of its malaria burden. Chloroquine resistance in P. vivax is emerging in Asia.
Woodrow Charles J +9 more
doaj +2 more sources
A randomised controlled trial to assess the efficacy of dihydroartemisinin-piperaquine for the treatment of uncomplicated falciparum malaria in Peru. [PDF]
PLoS ONE, 2007 BackgroundMulti-drug resistant falciparum malaria is an important health problem in the Peruvian Amazon region. We carried out a randomised open label clinical trial comparing mefloquine-artesunate, the current first line treatment in this region, with ...
Tanilu Grande +9 more
doaj +2 more sources
Quantification of the antimalarial piperaquine in plasma
Transactions of the Royal Society of Tropical Medicine and Hygiene, 2008 Malaria is one of the most common parasitic diseases in the world, with up to three million deaths a year. Piperaquine is an antimalarial drug that was extensively used in China during the 1980s and has recently received renewed interest as a partner drug in artemisinin-based combination therapy.
Tarning, J, Lindegardh, N
openaire +3 more sources
Dihydroartemisinin–Piperaquine for the Prevention of Malaria in Pregnancy [PDF]
New England Journal of Medicine, 2016 Intermittent treatment with sulfadoxine-pyrimethamine is widely recommended for the prevention of malaria in pregnant women in Africa. However, with the spread of resistance to sulfadoxine-pyrimethamine, new interventions are needed.We conducted a double-blind, randomized, controlled trial involving 300 human immunodeficiency virus (HIV)-uninfected ...
Kakuru, Abel +17 more
openaire +6 more sources
Reduced Exposure to Piperaquine, Compared to Adults, in Young Children Receiving Dihydroartemisinin‐Piperaquine as Malaria Chemoprevention [PDF]
Clinical Pharmacology & Therapeutics, 2019 Dihydroartemisinin (DHA)‐piperaquine is being evaluated as intermittent preventive therapy for malaria, but dosing has not been optimized for children. We assessed exposure to DHA and piperaquine in Ugandan children at two ages during infancy. Intensive sampling was performed in 32 children at 32 weeks of age, 31 children at 104 weeks, and 30 female ...
Whalen, Meghan E +11 more
openaire +6 more sources
Population Pharmacokinetics of Piperaquine in Young Ugandan Children Treated With Dihydroartemisinin‐Piperaquine for Uncomplicated Malaria [PDF]
Clinical Pharmacology & Therapeutics, 2015 This prospective trial investigated the population pharmacokinetics of piperaquine given with dihydroartemisinin to treat uncomplicated malaria in 107 Ugandan children 6 months to 2 years old, an age group previously unstudied. Current weight‐based dosing does not adequately address physiological changes in early childhood.
Sambol, N C +13 more
core +6 more sources
BMC Complementary Medicine and Therapies, 2022 Background: The WHO recommends artemisinin-based combination regimens for uncomplicated Plasmodium falciparum malaria. One such combination is artemisinin-piperaquine tablets (ATQ).
Xiaobo Li +9 more
doaj +3 more sources
Pitfalls in Estimating Piperaquine Elimination [PDF]
Antimicrobial Agents and Chemotherapy, 2005 ABSTRACT By using a sensitive new assay, the terminal elimination half-life of the antimalarial piperaquine in a healthy volunteer was estimated to be 33 days, which is longer than estimated previously. This result illustrates the importance of extended sampling duration and sensitive assay methodologies in characterizing the disposition of ...
Tarning, J +6 more
openaire +4 more sources
Piperaquine concentration and malaria treatment outcomes in Ugandan children treated for severe malaria with intravenous Artesunate or quinine plus Dihydroartemisinin-Piperaquine [PDF]
BMC Infectious Diseases, 2019 Background Treatment for severe malaria must be prompt with effective parenteral antimalarial drugs for at least 24 h to achieve fast parasite clearance, and when the patient can tolerate oral therapy, treatment should be completed with effective ...
Pauline Byakika-Kibwika +4 more
doaj +2 more sources